Review
doi: 10.1160/TH09-10-0716.
Epub 2010 Feb 2.
Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics
Affiliations
- PMID: 20135076
- DOI: 10.1160/TH09-10-0716
Item in Clipboard
Review
Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics
Thromb Haemost.
2010 Mar.
Abstract
Antithrombotic therapy for the acute management of thrombotic disorders has been stimulated and guided actively by our current understanding of platelet biology, coagulation proteases, and vascular science. A translatable platform for coagulation, based soundly on biochemistry, enzymology and cellular events on platelets and tissue factor-baring cells, introduces fundamental constructs, mechanistic clarity, and an unparalleled opportunity for accelerating the development and clinical investigation of both disease- and patient-specific therapies. In the current review, we build upon and expand substantially our observations surrounding nucleic acids as antithrombotic agents.
Similar articles
-
Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.Ann N Y Acad Sci. 2009 Sep;1175:61-70. doi: 10.1111/j.1749-6632.2009.05017.x. Ann N Y Acad Sci. 2009. PMID: 19796078
-
Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy.Hamostaseologie. 2007 Dec;27(5):378-82. Hamostaseologie. 2007. PMID: 18060250
-
Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.J Cardiovasc Transl Res. 2010 Dec;3(6):704-16. doi: 10.1007/s12265-010-9230-6. Epub 2010 Nov 16. J Cardiovasc Transl Res. 2010. PMID: 21080135 Review.
-
Regulatable aptamers in medicine: focus on antithrombotic strategies.Expert Opin Biol Ther. 2004 Oct;4(10):1641-7. doi: 10.1517/14712598.4.10.1641. Expert Opin Biol Ther. 2004. PMID: 15461575 Review.
-
Nucleic acid aptamers as adjuncts to vaccine development.Curr Opin Mol Ther. 2006 Apr;8(2):122-9. Curr Opin Mol Ther. 2006. PMID: 16610764 Review.
Cited by
-
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.Eur Heart J. 2013 Aug;34(31):2481-9. doi: 10.1093/eurheartj/ehs232. Epub 2012 Aug 2. Eur Heart J. 2013. PMID: 22859796 Free PMC article. Clinical Trial.
-
Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO.Mol Ther Nucleic Acids. 2021 Dec 11;27:524-534. doi: 10.1016/j.omtn.2021.12.011. eCollection 2022 Mar 8. Mol Ther Nucleic Acids. 2021. PMID: 35036063 Free PMC article.
-
Aptamer Conjugated RNA/DNA Hybrid Nanostructures Designed for Efficient Regulation of Blood Coagulation.Methods Mol Biol. 2023;2709:277-286. doi: 10.1007/978-1-0716-3417-2_19. Methods Mol Biol. 2023. PMID: 37572288 Free PMC article.
-
Parallel G-quadruplex Structures Increase Cellular Uptake and Cytotoxicity of 5-Fluoro-2'-deoxyuridine Oligomers in 5-Fluorouracil Resistant Cells.Molecules. 2021 Mar 20;26(6):1741. doi: 10.3390/molecules26061741. Molecules. 2021. PMID: 33804620 Free PMC article.
-
Thermodynamics of ligand binding to a heterogeneous RNA population in the malachite green aptamer.Biochemistry. 2012 Jan 10;51(1):565-72. doi: 10.1021/bi201642p. Epub 2011 Dec 16. Biochemistry. 2012. PMID: 22192051 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
